Ascendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "overweight" rating restated by research analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They currently have a $170.00 price objective on the biotechnology company's stock. Cantor Fitzgerald's target price suggests a potential upside of 35.17% from the stock's current price.

Other research analysts have also issued reports about the company. Oppenheimer reiterated an "outperform" rating and set a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Jefferies Financial Group raised their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a "buy" rating in a report on Tuesday, August 13th. TD Cowen upped their price target on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a "buy" rating in a report on Monday, October 21st. JPMorgan Chase & Co. lowered their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an "overweight" rating for the company in a research report on Wednesday, October 23rd. Finally, Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $195.92.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND traded up $0.49 during mid-day trading on Monday, hitting $125.77. 486,062 shares of the stock were exchanged, compared to its average volume of 444,783. The company has a market cap of $7.63 billion, a P/E ratio of -13.62 and a beta of 0.66. Ascendis Pharma A/S has a twelve month low of $86.54 and a twelve month high of $161.00. The stock's fifty day simple moving average is $133.42 and its two-hundred day simple moving average is $133.56.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. As a group, equities research analysts predict that Ascendis Pharma A/S will post -7.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP acquired a new position in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $992,000. Price T Rowe Associates Inc. MD raised its position in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock valued at $269,374,000 after purchasing an additional 336,976 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Ascendis Pharma A/S by 4,231.4% in the 1st quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company's stock valued at $11,419,000 after purchasing an additional 73,796 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Ascendis Pharma A/S by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company's stock valued at $1,664,000 after purchasing an additional 4,338 shares during the last quarter. Finally, Evolutionary Tree Capital Management LLC raised its holdings in shares of Ascendis Pharma A/S by 82.3% during the 2nd quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company's stock worth $3,391,000 after buying an additional 11,223 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.